FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1979668300> ?p ?o ?g. }

• W1979668300 endingPage "158" @default.
• W1979668300 startingPage "153" @default.
• W1979668300 abstract "Background: Angiotensin type 1 receptor (AT1R) antagonists are extensively used for blood pressure control in elderly patients with hypertension. This study aimed to investigate the inhibitory effects of AT1R antagonist valsartan on platelet aggregation and the occurrence of cardio-cerebral thrombotic events in elderly patients with hypertension. Methods: Two-hundred and ten patients with hypertension and aged > 60 years were randomized to valsartan (n = 140) or amlodipine (n = 70) on admission. The primary endpoint was platelet aggregation rate (PAR) induced by arachidonic acid at discharge, and the secondary endpoint was the rate of thrombotic events including brain infarction and myocardial infarction during follow-up. Human aortic endothelial cells (HAECs) were stimulated by angiotensin II (Ang II, 100 nmol/L) with or without pretreatment of valsartan (100 nmol/L), and relative expression of cyclooxygenase-2 (COX-2) and thromboxane B2 (TXB2) and both p38 mitogen-activated protein kinase (p38MAPK) and nuclear factor-kB (NF-kB) activities were assessed. Statistical analyses were performed by GraphPad Prism 5.0 software (GraphPad Software, Inc., California, USA). Results: PAR was lower after treatment with valsartan (11.49 ± 0.69% vs. 18.71 ± 2.47%, P < 0.001), associated with more reduced plasma levels of COX-2 (76.94 ± 7.07 U/L vs. 116.4 ± 15.89 U/L, P < 0.001) and TXB2 (1667 ± 56.50 pg/ml vs. 2207 ± 180.20 pg/ml) (all P < 0.001). Plasma COX-2 and TXB2 levels correlated significantly with PAR in overall patients (r = 0.109, P < 0.001). During follow-up (median, 18 months), there was a significantly lower thrombotic event rate in patients treated with valsartan (14.3% vs. 32.8%, P = 0.002). Relative expression of COX-2 and secretion of TXB2 with concordant phosphorylation of p38MAPK and NF-kB were increased in HAECs when stimulated by Ang II (100 nmol/L) but were significantly decreased by valsartan pretreatment (100 nmol/L). Conclusions: AT1R antagonist valsartan decreases platelet activity by attenuating COX-2/TXA2 expression through p38MAPK and NF-kB pathways and reduces the occurrence of cardio-cerebral thrombotic events in elderly patients with hypertension." @default.
• W1979668300 created "2016-06-24" @default.
• W1979668300 creator A5015217068 @default.
• W1979668300 creator A5016881112 @default.
• W1979668300 creator A5026394330 @default.
• W1979668300 creator A5054847996 @default.
• W1979668300 creator A5056960644 @default.
• W1979668300 creator A5063794764 @default.
• W1979668300 creator A5067338135 @default.
• W1979668300 creator A5070544831 @default.
• W1979668300 creator A5084138890 @default.
• W1979668300 creator A5088528419 @default.
• W1979668300 date "2015-01-20" @default.
• W1979668300 modified "2023-09-27" @default.
• W1979668300 title "Valsartan Decreases Platelet Activity and Arterial Thrombotic Events in Elderly Patients with Hypertension" @default.
• W1979668300 cites W1803320375 @default.
• W1979668300 cites W1973922450 @default.
• W1979668300 cites W1980973689 @default.
• W1979668300 cites W2029634128 @default.
• W1979668300 cites W2036913490 @default.
• W1979668300 cites W2041415987 @default.
• W1979668300 cites W2058217708 @default.
• W1979668300 cites W2066371549 @default.
• W1979668300 cites W2073587768 @default.
• W1979668300 cites W2078516115 @default.
• W1979668300 cites W2082291507 @default.
• W1979668300 cites W2083313938 @default.
• W1979668300 cites W2096378972 @default.
• W1979668300 cites W2125471714 @default.
• W1979668300 cites W2135948072 @default.
• W1979668300 cites W2143954917 @default.
• W1979668300 cites W2146851676 @default.
• W1979668300 cites W2149984223 @default.
• W1979668300 cites W2156835140 @default.
• W1979668300 cites W2159357111 @default.
• W1979668300 cites W2170825031 @default.
• W1979668300 cites W2316315581 @default.
• W1979668300 cites W2325410873 @default.
• W1979668300 cites W2407845950 @default.
• W1979668300 cites W2427337960 @default.
• W1979668300 cites W2607031541 @default.
• W1979668300 doi "https://doi.org/10.4103/0366-6999.149185" @default.
• W1979668300 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4837831" @default.
• W1979668300 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25591555" @default.
• W1979668300 hasPublicationYear "2015" @default.
• W1979668300 type Work @default.
• W1979668300 sameAs 1979668300 @default.
• W1979668300 citedByCount "6" @default.
• W1979668300 countsByYear W19796683002017 @default.
• W1979668300 countsByYear W19796683002018 @default.
• W1979668300 countsByYear W19796683002019 @default.
• W1979668300 countsByYear W19796683002020 @default.
• W1979668300 countsByYear W19796683002021 @default.
• W1979668300 crossrefType "journal-article" @default.
• W1979668300 hasAuthorship W1979668300A5015217068 @default.
• W1979668300 hasAuthorship W1979668300A5016881112 @default.
• W1979668300 hasAuthorship W1979668300A5026394330 @default.
• W1979668300 hasAuthorship W1979668300A5054847996 @default.
• W1979668300 hasAuthorship W1979668300A5056960644 @default.
• W1979668300 hasAuthorship W1979668300A5063794764 @default.
• W1979668300 hasAuthorship W1979668300A5067338135 @default.
• W1979668300 hasAuthorship W1979668300A5070544831 @default.
• W1979668300 hasAuthorship W1979668300A5084138890 @default.
• W1979668300 hasAuthorship W1979668300A5088528419 @default.
• W1979668300 hasBestOaLocation W19796683001 @default.
• W1979668300 hasConcept C126322002 @default.
• W1979668300 hasConcept C134018914 @default.
• W1979668300 hasConcept C164705383 @default.
• W1979668300 hasConcept C2777387769 @default.
• W1979668300 hasConcept C2779646130 @default.
• W1979668300 hasConcept C2908929049 @default.
• W1979668300 hasConcept C3018697912 @default.
• W1979668300 hasConcept C500558357 @default.
• W1979668300 hasConcept C71924100 @default.
• W1979668300 hasConcept C84393581 @default.
• W1979668300 hasConcept C89560881 @default.
• W1979668300 hasConcept C98274493 @default.
• W1979668300 hasConceptScore W1979668300C126322002 @default.
• W1979668300 hasConceptScore W1979668300C134018914 @default.
• W1979668300 hasConceptScore W1979668300C164705383 @default.
• W1979668300 hasConceptScore W1979668300C2777387769 @default.
• W1979668300 hasConceptScore W1979668300C2779646130 @default.
• W1979668300 hasConceptScore W1979668300C2908929049 @default.
• W1979668300 hasConceptScore W1979668300C3018697912 @default.
• W1979668300 hasConceptScore W1979668300C500558357 @default.
• W1979668300 hasConceptScore W1979668300C71924100 @default.
• W1979668300 hasConceptScore W1979668300C84393581 @default.
• W1979668300 hasConceptScore W1979668300C89560881 @default.
• W1979668300 hasConceptScore W1979668300C98274493 @default.
• W1979668300 hasIssue "2" @default.
• W1979668300 hasLocation W19796683001 @default.
• W1979668300 hasLocation W19796683002 @default.
• W1979668300 hasLocation W19796683003 @default.
• W1979668300 hasLocation W19796683004 @default.
• W1979668300 hasLocation W19796683005 @default.
• W1979668300 hasLocation W19796683006 @default.
• W1979668300 hasOpenAccess W1979668300 @default.
• W1979668300 hasPrimaryLocation W19796683001 @default.

• next